[1] |
LEE A W M, MA B B Y, NG W T, et al. Management of nasopharyngeal carcinoma: current practice and future perspective[J]. J Clin Oncol, 2015, 33(29): 3356-3364.
doi: 10.1200/JCO.2015.60.9347
pmid: 26351355
|
[2] |
BLANCHARD P, LEE A, MARGUET S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis[J]. Lancet Oncol, 2015, 16(6): 645-655.
doi: 10.1016/S1470-2045(15)70126-9
pmid: 25957714
|
[3] |
ZHANG M X, LI J, SHEN G P, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up[J]. Eur J Cancer, 2015, 51(17): 2587-2595.
doi: 10.1016/j.ejca.2015.08.006
|
[4] |
SUN X M, SU S F, CHEN C Y, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities[J]. Radiother Oncol, 2014, 110(3): 398-403.
doi: 10.1016/j.radonc.2013.10.020
pmid: 24231245
|
[5] |
COLEVAS A D, YOM S S, PFISTER D G, et al. NCCN guidelines insights: head and neck cancers, version 1.2018[J]. J Natl Compr Canc Netw, 2018, 16(5): 479-490.
doi: 10.6004/jnccn.2018.0026
|
[6] |
SUN W, ZHANG L L, LUO M, et al. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio[J]. Head Neck, 2016, 38(Suppl 1): E1332-E1340.
|
[7] |
JIN T, LIU N F, JIN Q F, et al. Radiation dose escalation for locally advanced nasopharyngeal carcinoma patients with local and/or regional residual lesions after standard chemoradiotherapy: a non-randomized, observational study[J]. Radiat Oncol, 2022, 17(1): 176.
doi: 10.1186/s13014-022-02147-7
pmid: 36345003
|
[8] |
CORBEAU A, KUIPERS S C, DE BOER S M, et al. Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review[J]. Radiother Oncol, 2021, 164: 128-137.
doi: 10.1016/j.radonc.2021.09.009
pmid: 34560187
|
[9] |
ZHAI R P, KONG F F, DU C R, et al. Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: clinical and dosimetric predictors in a prospective cohort study[J]. Oral Oncol, 2017, 68: 44-49.
doi: 10.1016/j.oraloncology.2017.03.005
|
[10] |
TERRONES-CAMPOS C, LEDERGERBER B, VOGELIUS I R, et al. Hematological toxicity in patients with solid malignant tumors treated with radiation-temporal analysis, dose response and impact on survival[J]. Radiother Oncol, 2021, 158: 175-183.
doi: 10.1016/j.radonc.2021.02.029
|
[11] |
LIU L T, LIANG Y J, GUO S S, et al. Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA[J]. Head Neck, 2022, 44(1): 34-45.
doi: 10.1002/hed.v44.1
|
[12] |
TANG C, LIAO Z X, GOMEZ D, et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes[J]. Int J Radiat Oncol Biol Phys, 2014, 89(5): 1084-1091.
doi: 10.1016/j.ijrobp.2014.04.025
|
[13] |
JOSEPH N, MCWILLIAM A, KENNEDY J, et al. Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy[J]. Radiother Oncol, 2019, 135: 115-119.
doi: S0167-8140(19)30112-4
pmid: 31015156
|
[14] |
DAVULURI R, JIANG W, FANG P, et al. Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy[J]. Int J Radiat Oncol Biol Phys, 2017, 99(1): 128-135.
doi: 10.1016/j.ijrobp.2017.05.037
|
[15] |
WEEKE E. The development of lymphopenia in uremic patients undergoing extracorporeal irradiation of the blood with portable beta units[J]. Radiat Res, 1973, 56(3): 554-559.
pmid: 4767134
|
[16] |
XIE X X, GONG S L, JIN H K, et al. Radiation-induced lymphopenia correlates with survival in nasopharyngeal carcinoma: impact of treatment modality and the baseline lymphocyte count[J]. Radiat Oncol, 2020, 15(1): 65.
doi: 10.1186/s13014-020-01494-7
pmid: 32169088
|
[17] |
HIRATA F, ISHIYAMA K, TANAKA Y, et al. Effect of bevacizumab plus XELOX (CapeOX) chemotherapy on liver natural killer cell activity in colorectal cancer with resectable liver metastasis[J]. Ann Gastroenterol Surg, 2018, 2(5): 383-393.
doi: 10.1002/ags3.12195
pmid: 30238080
|
[18] |
XIANG X Y, DING Z, ZENG Q, et al. Dosimetric parameters and absolute monocyte count can predict the prognosis of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemotherapy and volumetric-modulated arc therapy[J]. Radiat Oncol, 2022, 17(1): 48.
doi: 10.1186/s13014-022-02018-1
|
[19] |
CHUA M L, TAN S H, KUSUMAWIDJAJA G, et al. Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: a pooled analysis of two randomised controlled trials[J]. Eur J Cancer, 2016, 67: 119-129.
doi: 10.1016/j.ejca.2016.08.006
pmid: 27640138
|
[20] |
LI X H, CHANG H, XU B Q, et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study[J]. Cancer Med, 2017, 6(1): 310-319.
doi: 10.1002/cam4.2017.6.issue-1
|
[21] |
CHO O, OH Y T, CHUN M, et al. Minimum absolute lymphocyte count during radiotherapy as a new prognostic factor for nasopharyngeal cancer[J]. Head Neck, 2016, 38(Suppl 1): E1061-E1067.
|
[22] |
LIU L T, CHEN Q Y, TANG L Q, et al. The prognostic value of treatment-related lymphopenia in nasopharyngeal carcinoma patients[J]. Cancer Res Treat, 2018, 50(1): 19-29.
doi: 10.4143/crt.2016.595
|
[23] |
VENKATESULU B P, MALLICK S, LIN S H, et al. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors[J]. Crit Rev Oncol Hematol, 2018, 123: 42-51.
doi: S1040-8428(17)30349-9
pmid: 29482778
|
[24] |
DU C R, NI M S, JIANG J Y, et al. Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis[J]. Eur Arch Otorhinolaryngol, 2022, 279(8): 3947-3956.
doi: 10.1007/s00405-021-07192-8
pmid: 34981158
|
[25] |
LEE Y J, AUH S L, WANG Y G, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment[J]. Blood, 2009, 114(3): 589-595.
|
[26] |
SO T H, LAM K O. The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy: Asian perspectives in the immunotherapy era[J]. Radiother Oncol, 2020, 147: 144.
doi: 10.1016/j.radonc.2020.05.025
|
[27] |
RYBKINA V L, AZIZOVA T V, SCHERTHAN H, et al. Expression of blood serum proteins and lymphocyte differentiation clusters after chronic occupational exposure to ionizing radiation[J]. Radiat Environ Biophys, 2014, 53(4): 659-670.
doi: 10.1007/s00411-014-0556-3
pmid: 25073961
|
[28] |
BALÁZS K, KIS E, BADIE C, et al. Radiotherapy-induced changes in the systemic immune and inflammation parameters of head and neck cancer patients[J]. Cancers (Basel), 2019, 11(9): 1324.
doi: 10.3390/cancers11091324
|
[29] |
LUO-OWEN X, PECAUT M J, RIZVI A, et al. Low-dose total-body γ irradiation modulates immune response to acute proton radiation[J]. Radiat Res, 2012, 177(3): 251-264.
doi: 10.1667/RR2785.1
|
[30] |
WANG L J, GUO Y S, XU J H, et al. Clinical analysis of recurrence patterns in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy[J]. Ann Otol Rhinol Laryngol, 2017, 126(12): 789-797.
doi: 10.1177/0003489417734229
|
[31] |
SANFORD N N, LAU J, LAM M B, et al. Individualization of clinical target volume delineation based on stepwise spread of nasopharyngeal carcinoma: Outcome of more than a decade of clinical experience[J]. Int J Radiat Oncol Biol Phys, 2019, 103(3): 654-668.
doi: 10.1016/j.ijrobp.2018.10.006
|
[32] |
BYUN H K, KIM N, YOON H I, et al. Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era[J]. Radiat Oncol, 2019, 14(1): 51.
doi: 10.1186/s13014-019-1256-6
pmid: 30917849
|
[33] |
WANG X, ZHAO Z X, WANG P L, et al. Low lymphocyte count is associated with radiotherapy parameters and affects the outcomes of esophageal squamous cell carcinoma patients[J]. Front Oncol, 2020, 10: 997.
doi: 10.3389/fonc.2020.00997
pmid: 32656085
|
[34] |
JIN J Y, HU C, XIAO Y, et al. Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage Ⅲ NSCLC: a secondary analysis of RTOG0617[J]. Cancers (Basel), 2021, 13(24): 6193.
doi: 10.3390/cancers13246193
|
[35] |
VENKATESULU B, GIRIDHAR P, PUJARI L, et al. Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): a systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy[J]. Radiother Oncol, 2022, 177: 81-94.
doi: 10.1016/j.radonc.2022.10.019
pmid: 36334694
|
[36] |
WANG Y F, DENG W Y, LI N, et al. Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions[J]. Front Pharmacol, 2018, 9: 185.
doi: 10.3389/fphar.2018.00185
pmid: 29556198
|